FY27: 6 MON BRIDGE Ortho Clinical-Pathology & Lab

Award Notice Posted

Solicitation number
36C24727F0328
Agency
Awarded
Set-aside
No set-aside

Opportunity facts

Contract number
V797D-60637-36C24727F0328
Place of performance
Georgia, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Veterans Health Administration, Veterans Integrated Service Network 7, awarded a six-month bridge contract valued at $54,647.20 to QUIDELORTHO SALES COMPANY, LLC on October 1, 2026, to provide blood bank ortho clinical reagents and related supplies for the Atlanta VA Medical Center.

The award was made under a sole source justification against existing FSS Contract V797D-60637. The requirement spans MTS A/B/D monoclonal grouping reagents, MTS ANTI-IGG, Affirmagen, Resolve A and B, Ortho Daily QC controls, MTS DAT cards, Antibody Identification Software, MTS Round Dilution products, Ortho 7% BSA, OV Single Use Dilution Trays, and OV Single Use Evaporation Caps in quantities adjusted monthly to meet Type and Screen testing, Direct Antiglobulin Testing, and ABO/Rh confirmation demands. The contracting officer justified the sole source selection on urgent operational need—standard competitive procedures would cause unacceptable delays to patient care during the gap before the current task order expired September 30, 2026—and on sole capability: QUIDELORTHO's supplies are uniquely compatible with the facility's existing Ortho VISION analyzers and software, with no competitor able to establish equivalent equipment and training within the required two-week timeframe. A competitive RFQ will be issued to FSS contract holders upon bridge completion to establish long-term pricing and enable vendor transition if warranted.

Notice text

This is a follow-on six (6) Month bridge contract needed to continue blood bank ortho clinical reagent lease for the Atlanta VA Medical Center. Requirement is to provide MTS A/B/D MONO & REV GRP, MTS A/B/D Monoclonal Grouping, MTS A/B Monoclonal Grouping, MTS ANTI-IGG, 0.8% AFFIRMAGEN, 0.8% RESOLVE A, 0.8% RESOLVE B, 0.8% SURG, Ortho Daily QC SWB CONTROLS, MTS DAT Cards, Antibody Identification Software, MTS ROUND DIL2, and MTS ROUND DIL2+, Ortho 7 % BSA, OV Single Use Dilution Trays, and OV Single Use Evaporation Caps 250 in such quantities as determined by the consumer each month to meet the hospital’s Type and Screen testing demands. Based on increased demands for Type and Screens, Direct Antiglobulin Testing, and ABO/Rh Confirmations, the end user may adjust the volume of items required to meet the hospital’s demands. (SOLICITATION IS GOING TO BE POSTED FOR LONGTERM AWARD, THIS IS ONLY TO REMAIN SERVICES TO ALLOW COMP)

Awarded contract V797D-60637 to QUIDELORTHO SALES COMPANY, LLC for 54647.20 on 2026-10-01.

Files

File Type Posted
JA ORTHO 1_Redacted.pdf PDF

Similar open opportunities

Opportunity Agency Set-aside Responses due
Q301--FY27 (BASE+4) STAT Laboratory Testing - Syracuse (VA-27-00010334) NAICS 621511 Veterans Integrated Service Network 2 No set-aside
7A21--Siemens UniPOC Licenses and Service NAICS 334516 VA Technology Acquisition Center No set-aside
6550--VISN 4 Coagulation Testing Pittsburgh, Pennsylvania 15215, United States · NAICS 334516 Veterans Integrated Service Network 4 No set-aside
6550--hemochron signature elite reagents and supplies Department of Veterans Affairs Southern Arizona Healthcare System Tucson AZ 85723 · NAICS 325413 Veterans Integrated Service Network 22 No set-aside
6550--Cepheid GeneXpert Testing Supplies Beckley Vamc Clarksburg Vamc Vamhcs Washington Vamc · NAICS 325413 Veterans Integrated Service Network 5 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity